Correlation Engine 2.0
Clear Search sequence regions

  • candida albicans (3)
  • candidiasis (9)
  • diseases and (1)
  • female (2)
  • humans (1)
  • patients (2)
  • research (1)
  • vagina (1)
  • women (2)
  • Sizes of these terms reflect their relevance to your search.

    Our aim was to determine the effect of immunomodulatory therapy in women with chronic and recurrent vulvovaginal candidiasis (RVVC). We present recent highlights in the research into vaginal microbiome and consequences of chronic inflammation such as vulvovaginal candidiasis (VVC). VVC is a widespread vaginal infection primarily caused by Candida albicans. Experience of more than three episodes per year is defined as RVVC. The strains were isolated from women suffering from the above infections as for the period of 2017 to 2021 and subsequently used in immunomodulatory treatment. The preparation and administration of autovaccination therapy was performed using standard methodology and procedures cited in the manuscript. In total, autovaccines were produced for 73 patients of whom 30 (41 %) were successfully cured by this treatment, 29 (40 %) experienced a partially successful treatment, and in the remaining 14 (19 %), the autovaccination therapy was ineffective. We provide current knowledge about alternative (autovaccine) treatment options for female patients with VVC and RVVC diseases and our experience with the outcomes after autovaccine administration that currently has a promising therapeutic potential (Tab. 2, Ref. 18). Text in PDF Keywords: autovaccines, chronic infections, vulvovaginal candidiasis, recurrent, Candida albicans.


    Jan Koren, Magdalena Zaborska, Ivan Varga, Jozef Zahumensky, Adriana Liptakova. Autovaccines - potent tool against chronic vulvovaginal candidiasis. Bratislavske lekarske listy. 2023;124(6):417-420

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36876375

    View Full Text